Placebo-adjusted mean weight loss of 11.3% (27.3 lbs) with 120 mg dose in the 36-week Phase 2b ACCESS study with a 10.4% adverse event-related treatment discontinuation Placebo-adjusted mean weight ...
Structure Therapeutics Inc. earns a Strong Buy rating following robust phase 2b data for oral GLP-1R agonist Aleniglipron in obesity. Aleniglipron achieved placebo-adjusted weight loss up to -15.3% at ...
Morning Overview on MSN
More vitamin C might change your skin’s structure, not just its glow
Vitamin C has long been sold as a shortcut to a brighter complexion, but the latest research suggests it is doing something ...
The engagement establishes a multi-phase framework to support AI enabled capital efficient development of Teverelix, a next generation GnRH antagonist, as a first in class market product for acute ...
How-To Geek on MSN
5 things I wish I knew when I first learned programming
When I was new to programming, I focused way too much on learning the syntax, especially the brackets, the semicolons, and ...
Highest Grade Channel Sample Results to Date at Munro-Croesus Returns 124 g/t Au over 0.62 m within 39.5 g/t Au over 2.3 m ...
Chinese AI startup’s release is a major update to its open-source model series, aimed at multi-language programming and ...
Potential to bring nuclear power, scalable eSAF production, and environmental-attribute monetization together into a single, integrated clean-energy platform. Exploring advancing next-generation eSAF ...
Reconnaissance Energy Africa Ltd. (TSXV: RECO) (OTCQX: RECAF) (FSE: 0XD) (NSX: REC) (the “Company” or “ReconAfrica” or “Recon”) announces ...
VANCOUVER, BC / ACCESS Newswire / December 22, 2025 / Prospect Ridge Resources Corp. (the "Company" or "Prospect Ridge") (CSE ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback